ANG Lifesciences India Ltd
NSE: BSE: 540694
₹36.17
(4.99%)
Sun, 18 Oct 2026, 07:59 pm
Market Cap (in Cr)42.84
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KANG Lifesciences India Income Statement
| Particulars | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 753.29M | 1.21B | 1.26B | 1.54B | 3.54B | 2.20B | 1.45B | 926.02M |
| Gross profit | 109.43M | 198.81M | 216.61M | 269.03M | 834.76M | 232.97M | 155.67M | 22.04M |
| Operating expenses (excl. COGS) | -48.70M | -90.43M | -99.25M | -138.13M | -210.00M | -169.88M | -137.35M | -86.91M |
| Selling/general/admin expenses, total | -43.42M | -76.21M | -94.92M | -133.90M | -194.44M | -162.29M | -129.66M | -87.93M |
| Research & development | — | — | — | 0 | — | — | 0 | 0 |
| Selling/general/admin expenses, other | -43.42M | -76.21M | -94.92M | -133.90M | -194.44M | -162.29M | -129.66M | -87.93M |
| Other operating expenses, total | -5.28M | -14.22M | -4.33M | -4.23M | -15.56M | -7.59M | -7.69M | 1.02M |
| Operating income | 60.73M | 108.38M | 117.36M | 130.90M | 624.76M | 63.09M | 18.32M | -64.87M |
| Non-operating income, total | -11.20M | -27.29M | -33.29M | -29.51M | -89.75M | -36.84M | -125.45M | -92.16M |
| Interest expense, net of interest capitalized | -18.06M | -26.13M | -31.90M | -33.33M | -94.22M | -124.81M | -114.08M | -90.53M |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 6.86M | -467.19K | -1.38M | 3.83M | 4.46M | 87.97M | -11.37M | -1.63M |
| Non-operating interest income | 1.31M | 1.55M | 3.18M | 2.00M | 2.86M | 6.41M | 5.28M | 2.26M |
| Miscellaneous non-operating expense | 5.55M | -2.02M | -4.56M | 1.83M | 1.61M | 81.56M | -16.65M | -3.89M |
| Unusual income/expense | 0 | -695.96K | -5.44K | 0 | 0 | 0 | 0 | 0 |
| Pretax income | 49.53M | 81.09M | 84.06M | 101.39M | 535.00M | 26.25M | -107.14M | -157.04M |
| Taxes | -12.29M | -24.60M | -23.11M | -31.11M | -131.84M | -28.87M | 5.71M | 32.90M |
| Non-controlling/minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 37.24M | 56.49M | 60.96M | 70.28M | 403.17M | -2.62M | -101.43M | -124.13M |
| Net income | 37.24M | 56.49M | 60.96M | 70.28M | 403.17M | -2.62M | -101.43M | -124.13M |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 37.24M | 56.49M | 60.96M | 70.28M | 403.17M | -2.62M | -101.43M | -124.13M |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - | - | - |
| EBITDA | 72.64M | 119.62M | 129.64M | 144.07M | 683.51M | 156.62M | 102.03M | 2.73M |
| EBIT | 60.73M | 108.38M | 117.36M | 130.90M | 624.76M | 63.09M | 18.32M | -64.87M |
| Total operating expenses | -692.56M | -1.11B | -1.15B | -1.41B | -2.92B | -2.13B | -1.44B | -990.90M |
| Prepaid expenses | 799.86K | 6.85M | 1.93M | 2.80M | 3.04M | 3.43M | 2.09M | 1.47M |
| Deferred income, current | 1.30M | 2.06M | 12.24M | 12.63M | 40.91M | 49.92M | 70.14M | 27.19M |
| Capital and operating lease obligations | 0 | 0 | 0 | 0 | 0 | 27.73M | 27.73M | 18.70M |
| Operating lease liabilities | — | — | — | — | — | — | — | — |
| Deferred tax liabilities | 3.70M | 3.97M | 3.59M | 3.53M | 6.15M | 14.91M | 13.34M | — |
| Deferred income, non-current | — | — | — | — | — | — | — | — |
| Minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in accrued expenses | — | — | — | — | — | — | — | — |
| Common dividends paid | 0 | 0 | 0 | 0 | -10.35M | 0 | 0 | 0 |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
